DUBLIN--(BUSINESS WIRE)--The "Kv1.3 Potassium Channel Blockers -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
'Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Kv1.3 Potassium Channel Blockers development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Descriptive coverage of pipeline development activities for Kv1.3 Potassium Channel Blockers - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Kv1.3 Potassium Channel Blockers - Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Kv1.3 Potassium Channel Blockers Pipeline Products in Clinical Stages
6. Kv1.3 Potassium Channel Blockers Pipeline Products in Non-clinical Stages
7. Therapeutic Assessment: Active Products
8. Inactive Pipeline Products
Companies Mentioned
- Kineta
- Sevion Therapeutics
- Cono Genetix
- KPI Therapeutics
-
Amgen
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vgzcc6/kv1_3_potassium?w=4
